Abstract
Some of the several effects of sodium-glucose cotransporter-2 inhibitors (SGLT-2i), including their metabolic, anti-inflammatory and hemodynamic properties, along with other kidney protective values, have directed clinicians to give these drugs in IgA-nephropathy (IgAN). According to recent studies regarding the beneficial effects of SGLT-2i on IgAN, it is clear that clinicians are changing their approach towards kidney transplantation when it comes to aggressive immunosuppression. This mini-review aims towards the evaluation of the protective efficacy of SGLT-2i in IgA-nephropathy.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
